Literature DB >> 23879960

Inflammatory cytokines in human pancreatic cancer.

Rozita Roshani1, Fiona McCarthy2, Thorsten Hagemann3.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with poor prognosis. Despite extensive efforts, the current treatment methods have limited success. Therefore, novel therapeutic approaches are required. The pancreatic tumor microenvironment is rich in growth factors and inflammatory cytokines that support tumor growth, and it is highly immunosuppressive. Up-regulation of cytokine pathways has been shown to modulate PDAC progression and immune evasion; therefore targeting cytokines may have therapeutic benefits. In this review we provide an overview of current understanding of pro- and anti-inflammatory cytokines in pancreatic cancer and their potential as therapeutic targets.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cytokine; Immune evasion; Inflammation; Pancreatic cancer

Mesh：

Substances：

Year:  2013        PMID： 23879960     DOI： 10.1016/j.canlet.2013.07.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  53 in total

1.  Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.

Authors:  Gina L Razidlo; Christopher Magnine; Arthur C Sletten; Rachel M Hurley; Luciana L Almada; Martin E Fernandez-Zapico; Baoan Ji; Mark A McNiven
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

2.  Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.

Authors:  Xiaojuan Wu; Yang Cao; Hui Xiao; Chenglong Li; Jiayuh Lin
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

3.  GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.

Authors:  Shu Z Wiley; Krishna Sriram; Wenjing Liang; Sarah E Chang; Randall French; Thalia McCann; Jason Sicklick; Hiroshi Nishihara; Andrew M Lowy; Paul A Insel
Journal:  FASEB J       Date:  2018-01-03       Impact factor: 5.191

Review 4.  Metabolic implications of pancreatic fat accumulation.

Authors:  Robert Wagner; Sabine S Eckstein; Hajime Yamazaki; Felicia Gerst; Jürgen Machann; Benjamin Assad Jaghutriz; Annette Schürmann; Michele Solimena; Stephan Singer; Alfred Königsrainer; Andreas L Birkenfeld; Hans-Ulrich Häring; Andreas Fritsche; Susanne Ullrich; Martin Heni
Journal:  Nat Rev Endocrinol       Date:  2021-10-20       Impact factor: 43.330

5.  Orthotopic inflammation-related pancreatic carcinogenesis in a wild-type mouse induced by combined application of caerulein and dimethylbenzanthracene.

Authors:  Chen Liang; Zhen Wang; Li Wu; Chen Wang; Bao-Hua Yu; Xiu-Zhong Yao; Xiao-Lin Wang; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-04-29

6.  Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes.

Authors:  Brian Z Huang; Alexandra M Binder; Catherine A Sugar; Chun R Chao; Veronica Wendy Setiawan; Zuo-Feng Zhang
Journal:  Epigenomics       Date:  2020-09-01       Impact factor: 4.778

7.  The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?

Authors:  Ryan M Thomas; Christian Jobin
Journal:  Trends Cancer       Date:  2015-09-01

8.  Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.

Authors:  Ioannis Pozios; Thomas Knösel; Yue Zhao; Gerald Assmann; Iraklis Pozios; Mario H Müller; Christiane J Bruns; Martin E Kreis; Hendrik Seeliger
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-25       Impact factor: 4.553

9.  Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.

Authors:  Shintaro Tsukinaga; Mikio Kajihara; Kazuki Takakura; Zensho Ito; Tomoya Kanai; Keisuke Saito; Shinichiro Takami; Hiroko Kobayashi; Yoshihiro Matsumoto; Shunichi Odahara; Kan Uchiyama; Hiroshi Arakawa; Masato Okamoto; Haruo Sugiyama; Kazuki Sumiyama; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.

Authors:  Alexandra M Moore; Lei Zhou; Jing Cui; Luyi Li; Nanping Wu; Alice Yu; Soumya Poddar; Keke Liang; Evan R Abt; Stephanie Kim; Razmik Ghukasyan; Nooneh Khachatourian; Kristina Pagano; Irmina Elliott; Amanda M Dann; Rana Riahi; Thuc Le; David W Dawson; Caius G Radu; Timothy R Donahue
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.